Coherus Oncology, Inc.

Good day and thank you for standing by. Welcome to the Coherus Biosciences second quarter 2024 earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Jamie Taylor, Head of Investor Relations. Please go ahead.

Thank you, Operator. Good afternoon and welcome to Coherus Biosciences' second quarter 2024 earnings conference call. Joining me today to discuss our results are Denny Lanphier, Chief Executive Officer of Coherus, Brian McMichael, Chief Financial Officer, Paul Reeder, Chief Commercial Officer, Dr. Rosh Diaz, Chief Medical Officer, and Dr. Theresa Lavalley, Chief Development Officer. Before we get started, I would like to remind you that today's call includes forward-looking statements regarding COHERIS's current expectations about future events. These statements include, but are not limited to, the following. expectations for the timing of future clinical studies, expectations about future partnerships, projections of future revenue and expenses. All of these forward-looking statements involve substantial risks and uncertainties that are beyond our control and could cause actual results, performance, or achievements to differ from those implied by the forward-looking statements. These statements are not guarantees of future performance and are subject to substantial risks and uncertainties, including risks and uncertainties inherent in the clinical drug development process that are discussed in our press release that we issued today, as well as the documents that we file with the FCC. Forward-looking statements provided on the call today are made as of this date, and we undertake no duty to update or revise any forward-looking statement. And now I'll turn the call over to Denny.

Thank you, Jamie. Good afternoon, everyone, and thank you for joining us. Today we're pleased to share updates from the second quarter of 2024, a period in which we made definitive progress in executing upon our plan to align all aspects of our business to a focus on oncology. Our strategic focus on oncology is proving its merit. With streamlined operations and a recently streamlined portfolio, we grew total sales 10% year-over-year in the second quarter, from $59 million to $65 million, even without, similarly, the ophthalmology biosimilar we divested earlier this year. Udenica is delivering impressively as Lactorsi builds very nicely. As our Chief Commercial Officer, Paul Reeder, will describe shortly, the three presentations within our Udenica franchise continue to expand our opportunities in the marketplace. As the only brand offering three presentation options, refilled syringe, the auto-injector, and the on-body injector, we hold a clear competitive advantage that we believe will endure and increase over the long term. Our average selling price remains consistently strong, and our market share is growing. As an oncology company, our mission is to extend the survival of patients with cancer. Central to the fulfillment of that mission is Lactorsi. our first commercial immuno-oncology agent, which demonstrated a profound survival advantage in the data supporting its FDA approval late last year for the treatment of nasopharyngeal carcinoma. The launch of Lactorsi continues to proceed according to plan, and Paul will provide further updates on this during our call today. Beyond our commercial portfolio, we maintain our strong conviction in our pipeline of innovative immuno-oncology drug candidates. We are advancing clinical studies across areas of clear, unmet medical need, including head and neck cancers, non-small cell lung cancer, and hepatocellular carcinoma. Dr. Teresa Lavallee, our Chief Development Officer, and Dr. Raj Dias, our Chief Medical Officer, will describe these studies further on our call today. I'm especially pleased to report today that as a direct result of our continued efforts to manage our cash, reduce both our debt and headcount, Brian McMichael will report that we ended Q2 with $159 million on the balance sheet, positioning us well for the second half of this year and beyond. I'd like to congratulate Brian on the exceptional skill and leadership he has demonstrated since taking the role of interim CFO earlier this year. As announced in our press release this morning, Brian has now been appointed to the Chief Financial Officer role at O'Hare's, and with my support, the full support of the Board of Directors. Brian's deep financial expertise, owned throughout his time at Gilead Sciences, and further demonstrated since his arrival at Coherence a few years ago, gives me great confidence. My confidence extends to our product portfolio. Lactorsine, plus our competitively positioned pipeline, represents long-term value creation for shareholders. The pace of executing our strategy has been brisk. and we have strong momentum carrying us forward into the quarters ahead. And now with that, I'll turn the call over to Paul.